ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM
Abstract Number: 2509
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III
10:30AM-12:30PM
Abstract Number: 2164
Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
Patient Outcomes, Preferences, & Attitudes Poster III
10:30AM-12:30PM
Abstract Number: 1777
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Pediatric Rheumatology – Basic Science Poster
10:30AM-12:30PM
Abstract Number: 2505
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III
10:30AM-12:30PM
Abstract Number: 2375
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
SLE – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2037
Can Tofacitinib Be the Saviour in Treatment of Refractory IgG4-Related Disease : A Multicentre Experience from India
Miscellaneous Rheumatic & Inflammatory Diseases Poster III
10:30AM-12:30PM
Abstract Number: 2039
Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience
Miscellaneous Rheumatic & Inflammatory Diseases Poster III
10:30AM-12:30PM
Abstract Number: 2069
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 2275
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
RA – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2026
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Miscellaneous Rheumatic & Inflammatory Diseases Poster III
10:30AM-12:30PM
Abstract Number: 2379
Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2250
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2036
CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia
Miscellaneous Rheumatic & Inflammatory Diseases Poster III
10:30AM-12:30PM
Abstract Number: 1792
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster
10:30AM-12:30PM
Abstract Number: 2177
CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients
Pediatric Rheumatology – Clinical Poster III
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 61
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology